Jumpcode Genomics, a genome technology company focused on improving the understanding of human disease, has raised $21 million in a Series B round of funding.
The round was co-led by Baird Capital and Arboretum Ventures and included existing investor LYZZ Capital.
The company plans to use the to accelerate commercialization of the CRISPRclean technology, expand into additional market segments and further build our team, according to the company.
“Since emerging from stealth mode in late 2020, we’ve received robust interest in Jumpcode from the life sciences community,” said Yaron Hakak, CEO of Jumpcode Genomics. “Our CRISPRclean technology has helped scientists at renowned medical centers, academic and biotechnology organizations address research bottlenecks by depleting unwanted nucleic acid molecules from sequencing libraries, enabling them to see what they previously could not.”
In conjunction with the financing, Frank Witney will join Jumpcode’s Board of Directors, further expanding the company’s leadership team. Additionally, the company recently moved its headquarters into larger office and laboratory space.
To date, JumpCode has “a dozen technologies” in its intellectual property portfolio making their way through its development pipeline. A venture-backed startup, it employs a team of five.